VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

S. agalactiae BipA Protein Vaccine
Vaccine Information
  • Vaccine Name: S. agalactiae BipA Protein Vaccine
  • Target Pathogen: Streptococcus agalactiae
  • Target Disease: Group B streptococcus (GBS) infection
  • Vaccine Ontology ID: VO_0004200
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant BipA protein
  • BipA gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
    • Adjuvant name: complete Freunds adjuvant
    • VO adjuvant ID: VO_0000139
    • Description: Complete Freund's adjuvant on day 1, incomplete Freund's adjuvant on day 35 (Santi et al., 2009).
  • Adjuvant: incomplete Freunds adjuvant
  • Immunization Route: Intraperitoneal injection (i.p.)
Host Response

Mouse Response

  • Host Strain: CD‐1
  • Vaccination Protocol: Active mouse maternal immunization.A maternal immunization/neonatal pup challenge model of GBS infection was used to verify the protective efficacy of BibA protein in mice. CD‐1 female mice (6–8 weeks old) were immunized intraperitoneally on days 1 (complete Freund’s adjuvant), 21, and 35 (incomplete Freund’s adjuvant) with either PBS or 20 μg of recombinant protein and were then bred 3 days after the last immunization (Santi et al., 2009).
  • Challenge Protocol: Within 48 h of birth, pups were injected intraperitoneally with a dose of GBS strain 3050 that would be lethal to 90% of the population, corresponding to 3 x 104 colony‐forming units (CFU). Survival of pups was monitored for 3 days after challenge (Santi et al., 2009).
  • Efficacy: Immunization of mice with recombinant BibA conferred protection to 69% of the challenged pups (Santi et al., 2009).
References
Santi et al., 2009: Santi I, Maione D, Galeotti CL, Grandi G, Telford JL, Soriani M. BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus. The Journal of infectious diseases. 2009; 200(4); 564-570. [PubMed: 19586417].